Inclusion Criteria:  Age≥18 years。 Histology confirmed prostate cancer. Risk stratification, localised disease including patients with low-risk(cT1-T2a，PSA <10ng/mL，Gleason score≤6) who refuse active surveillance, favorable or unfavorable intermediate-risk and selected high-risk(cT2b-T3a or minimally T3b，PSA 10-40ng/mL，Gleason score 7-8) disease. Oligo-metastatic disease including patients with prostate in-situ and oligometastatic disease (no limit to mets number and organs, with all metastatic foci can be safely treated by radical SBRT dose) ECOG 0-2 Postate gland volume ≤100cc IPSS score of <18 Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed  Exclusion Criteria:  Contraindications to MRI. TURP within the past 6 months Ulcerative colitis, Crohn's Disease, ataxia telangiectasia, or systemic lupus erythematosus Previous pelvic irradiation Refuse contraception